false12-312023Q1000087401511P3Y6M0.3330.3330.3332026-04-302024-12-3100008740152023-01-012023-03-3100008740152023-04-2700008740152022-12-3100008740152023-03-310000874015ions:ConvertibleSeniorNotes0125PercentMember2023-03-310000874015ions:ConvertibleSeniorNotes0PercentMember2023-03-310000874015ions:ConvertibleSeniorNotes0PercentMember2022-12-310000874015ions:ConvertibleSeniorNotes0125PercentMember2022-12-310000874015ions:LicensingAndOtherRoyaltiesMember2023-01-012023-03-310000874015ions:ResearchAndDevelopmentRevenueMember2023-01-012023-03-310000874015ions:LicensingAndOtherRoyaltiesMember2022-01-012022-03-310000874015ions:CommercialMember2023-01-012023-03-310000874015ions:SpinrazaRoyaltiesMember2023-01-012023-03-310000874015ions:CollaborativeAgreementRevenueMember2023-01-012023-03-310000874015us-gaap:ProductMember2022-01-012022-03-310000874015ions:EplontersenJointDevelopmentRevenueMember2023-01-012023-03-3100008740152022-01-012022-03-310000874015us-gaap:ProductMember2023-01-012023-03-310000874015ions:EplontersenJointDevelopmentRevenueMember2022-01-012022-03-310000874015ions:ResearchAndDevelopmentRevenueMember2022-01-012022-03-310000874015ions:CollaborativeAgreementRevenueMember2022-01-012022-03-310000874015ions:SpinrazaRoyaltiesMember2022-01-012022-03-310000874015ions:CommercialMember2022-01-012022-03-3100008740152021-12-310000874015us-gaap:RetainedEarningsMember2022-12-310000874015us-gaap:CommonStockMember2021-12-310000874015us-gaap:CommonStockMember2022-12-310000874015us-gaap:AdditionalPaidInCapitalMember2021-12-310000874015us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000874015us-gaap:RetainedEarningsMember2021-12-310000874015us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000874015us-gaap:AdditionalPaidInCapitalMember2022-12-310000874015us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000874015us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000874015us-gaap:CommonStockMember2022-01-012022-03-310000874015us-gaap:RetainedEarningsMember2022-01-012022-03-310000874015us-gaap:RetainedEarningsMember2023-01-012023-03-310000874015us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000874015us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000874015us-gaap:CommonStockMember2023-01-012023-03-310000874015us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000874015us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000874015us-gaap:AdditionalPaidInCapitalMember2023-03-310000874015us-gaap:CommonStockMember2022-03-310000874015us-gaap:RetainedEarningsMember2022-03-310000874015us-gaap:CommonStockMember2023-03-310000874015us-gaap:AdditionalPaidInCapitalMember2022-03-310000874015us-gaap:RetainedEarningsMember2023-03-3100008740152022-03-310000874015ions:BiogenCollaborationsMember2023-01-012023-03-310000874015ions:GlaxoSmithKlineCollaborationMember2023-01-012023-03-310000874015ions:ConvertibleSeniorNotes0PercentMember2023-01-012023-03-310000874015ions:ConvertibleSeniorNotes0125PercentMember2023-01-012023-03-310000874015ions:CommercialRawMaterialsMember2023-03-310000874015ions:ClinicalRawMaterialsMember2022-12-310000874015ions:CommercialRawMaterialsMember2022-12-310000874015ions:ClinicalRawMaterialsMember2023-03-310000874015srt:MinimumMemberions:BiogenCollaborationsMember2023-03-310000874015ions:BiogenCollaboration2012NeurologyMember2023-01-012023-03-310000874015us-gaap:SubsequentEventMembersrt:MaximumMemberions:BiogenCollaboration2013StrategicNeurologyMember2023-04-300000874015srt:MaximumMemberions:BiogenCollaboration2012NeurologyMember2023-03-310000874015ions:BiogenCollaborationsMemberions:ResearchAndDevelopmentRevenueMember2023-01-012023-03-310000874015ions:BiogenCollaboration2013StrategicNeurologyMemberus-gaap:SubsequentEventMemberions:TofersenMember2023-04-012023-04-300000874015ions:BiogenCollaborationsMemberions:SpinrazaRoyaltiesMember2023-01-012023-03-310000874015ions:BiogenCollaborationsMemberions:ResearchAndDevelopmentRevenueMember2022-01-012022-03-310000874015ions:BiogenCollaborationsMember2022-01-012022-03-310000874015ions:BiogenCollaborationsMemberions:SpinrazaRoyaltiesMember2022-01-012022-03-310000874015ions:BiogenCollaborationsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000874015ions:BiogenCollaborationsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000874015ions:BiogenCollaborationsMember2022-12-310000874015ions:BiogenCollaborationsMember2023-03-310000874015srt:MinimumMemberions:GlaxoSmithKlineCollaborationMember2023-03-310000874015ions:GlaxoSmithKlineCollaborationMember2023-03-310000874015ions:GlaxoSmithKlineCollaborationMemberions:ResearchAndDevelopmentRevenueMember2022-01-012022-03-310000874015ions:BepirovirsenMemberions:GlaxoSmithKlineCollaborationMember2023-01-012023-03-310000874015ions:ResearchAndDevelopmentRevenueMemberions:GlaxoSmithKlineCollaborationMember2023-01-012023-03-310000874015us-gaap:RevenueFromContractWithCustomerMemberions:GlaxoSmithKlineCollaborationMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000874015ions:GlaxoSmithKlineCollaborationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-03-310000874015ions:GlaxoSmithKlineCollaborationMember2022-12-310000874015ions:ConvertibleSeniorNotes0PercentMember2022-03-310000874015ions:ConvertibleSeniorNotes0125PercentMember2022-03-310000874015us-gaap:CorporateDebtSecuritiesMember2022-12-310000874015us-gaap:OtherDebtSecuritiesMember2022-12-310000874015us-gaap:USTreasurySecuritiesMember2023-03-310000874015us-gaap:USStatesAndPoliticalSubdivisionsMember2022-12-310000874015us-gaap:USTreasurySecuritiesMember2022-12-310000874015us-gaap:USStatesAndPoliticalSubdivisionsMember2023-03-310000874015us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000874015us-gaap:CorporateDebtSecuritiesMember2023-03-310000874015us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310000874015ions:EquitySecuritiesPrivateCompaniesMember2022-12-310000874015ions:EquitySecuritiesPrivateCompaniesMember2023-03-310000874015ions:EquitySecuritiesPubliclyTradedCompaniesMember2023-03-310000874015ions:EquitySecuritiesPubliclyTradedCompaniesMember2022-12-310000874015ions:EquitySecuritiesPubliclyTradedCompaniesMember2023-01-012023-03-310000874015ions:EquitySecuritiesPrivateCompaniesMember2023-01-012023-03-310000874015us-gaap:FairValueMeasurementsRecurringMember2022-12-310000874015us-gaap:FairValueMeasurementsRecurringMember2023-03-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000874015us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000874015us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000874015us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000874015us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000874015us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000874015us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000874015us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-03-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2022-12-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000874015us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000874015us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-03-310000874015us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-03-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-03-310000874015us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310000874015us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2022-12-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-03-310000874015us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000874015us-gaap:FairValueInputsLevel2Member

SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.